Almirall is a global biopharmaceutical company focused on medical dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients’ needs. We find solutions for them. We aim to empower them. Almirall has 1 R&D center, 2 chemical plants and 2 pharmaceutical plants. Our more than 1,900 employees make it possible for our treatments to be available in over 100 countries across 5 continents, through our 15 global affiliates and via a strategic partnership network. Almirall is listed on the Spanish Stock Exchange (ticker: ALM).
시장 타임라인 및 시그널 피드 잠금 해제
최근 90일간 시그널 39건.
이 회사가 각 시장에 진입한 순서 — 오래된 순부터 최신 순까지
14 active postings
Facharztaußendienst Dermatologie (Biologika) (m/w/d), Region L1: Dresden, Cottbus, Görlitz, Wittenberg
가입하고 전체 시그널 피드를 확인하세요
Almirall의 글로벌 확장이 경쟁사와 비교해 어떤지
Almirall본 회사막대는 비교 대상 회사 간 상대적 규모를 나타냅니다.
열5| 회사 | 시장 | 신규 시장 | 모멘텀 | 활동 | 확장 점수 |
|---|---|---|---|---|---|
 Almirall본 회사 | 3 | 0 | +38% | 38 | 30 |
Product Manager (m/w/d) Atopic Dermatitis (AD)
공고 보기Hamburg, Hamburg, Germany · 3일 전
MEDICAL AFFAIRS SENIOR MANAGER Temporary
공고 보기Barcelona, Catalonia, Spain · 4일 전
IT BUSINESS PROCESS MANAGER
공고 보기Sant Andreu de la Barca, Catalonia, Spain · 6일 전
At Almirall, our "Act4Impact" strategy is the blueprint that integrates five vital pillars into our daily operations. This framework ensures our growth in medical dermatology is as responsible as it is innovative. Our commitment to a positive legacy includes: - Planet: A science-led roadmap toward Net Zero emissions. -People: Fostering a diverse and inclusive culture where our teams lead with integrity. - Patients: Placing people living with skin conditions at the core of every decision. - Part ...
종료됨For those living with chronic skin conditions, physical symptoms are only one part of the journey. Psychological distress, social isolation, and sleep disturbances can persist even after skin clearance. At Almirall, we aim to lead a paradigm shift. By integrating the WHO-5 Well-being Index into our clinical trials, we demonstrate our commitment to placing patient wellbeing at the heart of everything we do. Our goal is to transform the patient's world - addressing the person that lives behind the ...
종료됨For those living with chronic skin conditions, physical symptoms are only one part of the journey. Psychological distress, social isolation, and sleep disturbances can persist even after skin clearance. At Almirall, we aim to lead a paradigm shift. By integrating the WHO-5 Well-being Index into our clinical trials, we demonstrate our commitment to placing patient wellbeing at the heart of everything we do. Our goal is to transform the patient's world - addressing the person that lives behind the ...
종료됨Almirall 주주들이 Carlos Gallardo를 CEO로, Enrique de Leyva를 부사장으로 재선출했습니다. 회사는 주당 0.19유로의 유연한 배당금을 지급할 예정입니다.
Almirall 주주총회에서 Carlos Gallardo를 사장 겸 CEO로 재선출하고 주당 0.19유로의 유연한 배당금을 승인했습니다.
Qualifyze, 세계 최대 감사 데이터베이스를 활용한 AI 기반 제약 위험 관리 도구인 품질 인사이트 플랫폼 출시.
인증된 이메일과 직통 전화 잠금 해제
무료 · 신용카드 불필요
Almirall의 사업, 시장, 성장 시그널에 대한 빠른 답변입니다.
© 2026 Pubrio. 모든 권리 보유.
